Covered — thin cushion, one tenant family behind it. A quarterly payer at $0.75 a share, $3.00 annualized, raised 0.7% in June 2026 — and second-quarter FFO of $0.90 a share covered the $0.75 dividend at an 83% payout, up from $0.85 of FFO a year earlier. That is coverage, but at 83% there is little room for a bad quarter, and the concentration behind it is the real watch item: about 40% of 2025 revenue came from Universal Health Services, the founder-operator that also advises the trust, across a 77-investment portfolio in 21 states. The raise record is genuine — the June increase marked a 40th consecutive year of dividend growth — but a 7.96% yield on an 83% FFO payout is a market pricing concentration and payout thinness, not a bargain. For a REIT, the House reads FFO/AFFO payout — never the EPS payout, which depreciation makes meaningless.
Key risk: Universal Health Services concentration — about 40% of revenue from one operator family means a UHS facility decision, lease renegotiation, or operator stress reaches the rent roll faster than any diversification in the other 60% can offset.
Changes if: The FFO payout pushes past ~83% for a second quarter, UHS-linked rent weakens, or the credit facility draws further toward its $475 million limit. A payout back toward ~75% would start to repair this card.
- !AFFO coverage check: Second-quarter FFO of $0.90 a share covered the $0.75 dividend at an 83% payout — covered, but thin for a healthcare REIT, and the quarter's reported net income of $0.43 a share included a $0.06-a-share gain on a Chicago land sale, so the underlying $0.37 adjusted net income is thinner still. First-half FFO was $1.79 a share against $1.50 paid.
- ✓Growth check: The dividend was raised to $0.75 in June 2026, the 40th consecutive year of dividend growth, and FFO per share rose 5.9% year over year in the quarter on higher property income and lower borrowing costs. Growth is real but small — a 0.7% raise does not rebuild a cushion.
- !Leverage check: No debt-to-EBITDA figure is shown on this card: no clean company-reported June 30, 2026 debt-to-EBITDA figure was verified, so none is estimated here. What is verified is the credit line behind the payout — $365.6 million drawn on a $475 million facility at June 30, 2026, with $109.4 million of available capacity and a September 30, 2028 maturity.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.